Close
Smartlab Europe
Achema middle east

Drug Research

Regeneron Looks to Infusing More Funds into Gene Editing

Regeneron Pharmaceuticals is going ahead and investing more funds into gene editing, as it has announced a collaboration with Tessera Therapeutics in December 2025, so as to create an experimental program pertaining to rare liver and lung disease. At the...

FDA Looks to Accelerate Biosimilar Drug Development

The FDA has gone on to propose certain new policies in order to accelerate biosimilar drug development and at the same time also lower the cost pertaining to biosimilar agents when it comes to cancer as well as any...

J&J Buys Halda for $3bn to Own the Cell Death Platform

Johnson & Johnson will be paying $3.05 billion so as to acquire Halda Therapeutics, thereby getting a novel cell death platform while at the same time also strengthening its prostate cancer franchise that’s built on Erleada. At the mainstay of the...

In Silico and Virtual Trials: Revolutionizing Drug Development

Drug development is entering an era of radical transformation as pharmaceutical companies embrace virtual trials and in silico methodologies to reimagine the clinical research process. These digital-first strategies tap into computational models, artificial intelligence, and patient-specific simulations to address...

Injectable Drug Delivery System Innovations

Innovations in Injectable and Parenteral Drug Delivery Systems The evolution of injectable drug delivery systems marks a transformative period in pharmaceutical therapeutics, where technological sophistication converges with patient-centered design to revolutionize how medications reach their targets. Global market valuations exceeding...

Novel Excipients for Next Generation Drug Formulation

Exploring Novel Excipients for Next Generation Drug Formulation The landscape of pharmaceutical development finds itself at a critical juncture where the complexity of drug molecules increasingly outpaces the capabilities of traditional formulation approaches. Novel excipients drug formulation represents not merely...

Advances in Lipid-Based Drug Formulations for Solubility

Advances in Lipid-Based Drug Formulation for Solubility Enhancement The pharmaceutical industry faces a persistent challenge that threatens to derail promising drug candidates before they reach patients. Poor aqueous solubility afflicts over 70% of new molecular entities in development pipelines, creating...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »